Tengion Goes Public: IPO For Neo-Organ Firm Is Smaller Than Projected
This article was originally published in The Gray Sheet
Executive Summary
Tengion's recently completed, $30 million initial public stock offering will help support an ongoing Phase I trial of its Neo-Urinary Conduit biologic-device product
You may also be interested in...
News In Brief
Allergan’s Lap-Band
News In Brief
Allergan’s Lap-Band
People In Brief
Biomet Europe: Renaat Vermeulen, VP of sales, marketing and R&D in Europe, is promoted to the post of president of Biomet Europe to replace Roger van Broeck, who is retiring Sept. 1. Vermeulen will transition into his new role in the next several weeks, while van Broeck stays on as a company advisor through August, CEO Jeffrey Binder said July 13 during Biomet's fourth quarter earnings call